아미노글리코사이드계 항생제 시장 : 예측(2026-2031년)

Aminoglycosides Market is expected to increase at a 3.91% CAGR, growing from USD 1.619 billion in 2025 to USD 2.038 billion in 2031.

The aminoglycosides market encompasses a critical class of bactericidal antibiotics used to treat severe systemic infections caused by both gram-positive and gram-negative bacteria. Characterized by their concentration-dependent killing mechanism and efficacy against a broad spectrum of pathogens, these drugs remain essential agents in human and veterinary medicine, particularly for complicated and resistant infections.

Core Therapeutic Value and Clinical Imperative

Aminoglycosides, which include agents such as gentamicin and amikacin, are valued for their potent, rapid bactericidal activity. Their unique mechanism of action disrupts bacterial protein synthesis, making them effective even against large bacterial inocula. This profile solidifies their role as a cornerstone in the treatment of serious conditions including sepsis, hospital-acquired pneumonia, complicated urinary tract infections, and certain mycobacterial infections, notably tuberculosis. Their clinical use is often reserved for severe cases or as part of combination therapies to combat resistance and broaden antimicrobial coverage, underscoring their position as a vital tool in the antimicrobial armamentarium.

Primary Market Growth Drivers

Market demand is sustained by several persistent and interrelated global health challenges. The escalating prevalence of multi-drug resistant (MDR) bacterial infections is a paramount driver. As resistance to first-line antibiotics spreads, the reliance on second-line agents like aminoglycosides for treating MDR tuberculosis and other resistant gram-negative infections increases. This trend is compounded by the growing global incidence of infectious diseases, which maintains a steady baseline demand for effective antibiotic therapies.

Simultaneously, the market is experiencing significant expansion within veterinary medicine. The rising incidence of infectious disease outbreaks in livestock, poultry, and companion animals drives the consumption of aminoglycosides in feed, water, and therapeutic formulations. Their use in aquaculture further broadens the application base. This veterinary segment represents a substantial and growing component of overall market volume, supported by the intensification of global animal protein production.

Advancements in drug delivery systems present a significant growth vector aimed at mitigating the class's primary limitations: potential nephrotoxicity and ototoxicity. Research and development are focused on novel formulations, including sustained-release systems, liposomal encapsulation, and nanoparticle-based delivery. These innovations are designed to improve drug targeting, enhance efficacy, reduce dosing frequency, and lower the risk of adverse effects, thereby potentially expanding the safe and effective use of these antibiotics.

Key Market Segments and Agent Dynamics

The market is segmented by both application and specific agent. In terms of therapeutic area, the treatment of respiratory infections, particularly drug-resistant tuberculosis, represents a major and consistent revenue segment due to the high global burden of the disease, especially in developing regions.

Among individual agents, gentamicin maintains a dominant position due to its broad-spectrum efficacy, established clinical history, and cost-effectiveness. Its widespread use as a first-line agent in many healthcare settings, especially where resources are constrained, ensures continued high-volume demand. Amikacin is particularly significant for its role in treating infections resistant to other aminoglycosides, making it crucial in hospital settings for complex cases.

Geographic Landscape and Regulatory Environment

The Asia-Pacific region is projected to be the dominant and fastest-growing market. This is driven by a high burden of infectious diseases, including a significant prevalence of multi-drug resistant tuberculosis, which necessitates treatment with second-line aminoglycosides. The region's large population base, expanding healthcare infrastructure, and the presence of major manufacturing entities for both active pharmaceutical ingredients and finished formulations further consolidate its central role in global supply and consumption.

The market operates within a stringent and evolving regulatory framework globally. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce rigorous standards for the safety, efficacy, and quality of aminoglycoside production and distribution. Furthermore, guidelines from global health bodies promote antimicrobial stewardship, emphasizing the appropriate use of these agents-including therapeutic drug monitoring and combination therapy-to preserve their efficacy and minimize the development of resistance.

Competitive Landscape and Strategic Direction

The competitive environment includes established pharmaceutical companies specializing in anti-infectives and generic drug manufacturers. Strategic focus is bifurcated: one axis involves optimizing the production and supply of established, cost-effective agents like gentamicin for high-volume markets. The other, more innovation-focused axis involves investing in advanced formulation technologies to develop next-generation aminoglycoside products with improved safety profiles. Additionally, companies are engaged in lifecycle management strategies for existing drugs and exploring combination therapies to enhance therapeutic outcomes.

Future Market Trajectory

The future trajectory of the aminoglycosides market will be shaped by the persistent tension between rising antimicrobial resistance and the need for therapeutic innovation. While the class faces toxicity challenges, its irreplaceable efficacy against resistant pathogens ensures its continued necessity. Growth will be sustained by the ongoing veterinary demand and the critical human health need in managing MDR infections.

Long-term evolution depends on the successful clinical translation of advanced delivery systems that can demonstrably improve the therapeutic index. Furthermore, the market will remain sensitive to global antimicrobial stewardship policies and regulatory pressures aimed at curbing inappropriate use in both human and animal health. The aminoglycosides market, therefore, represents a mature but essential segment that is adapting to contemporary challenges through formulation science and strategic application, ensuring its role in managing serious bacterial infections for the foreseeable future.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Aminoglycosides Market Segmentation

• By Product
• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Others
• By Route of Administration
• Parenteral
• Intra-mammary
• Topical
• Oral
• By Application
• Veterinary
• Skin Infection
• Respiratory Diseases
• UTI and Pelvic Diseases
• Others
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AMINOGLYCOSIDES MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Neomycin
• 5.3. Tobramycin
• 5.4. Gentamicin
• 5.5. Amikacin
• 5.6. Paromomycin
• 5.7. Others

6. AMINOGLYCOSIDES MARKET BY ROUTE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Parenteral
• 6.3. Intra-mammary
• 6.4. Topical
• 6.5. Oral

7. AMINOGLYCOSIDES MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Veterinary
• 7.3. Skin Infection
• 7.4. Respiratory Diseases
• 7.5. UTI and Pelvic Diseases
• 7.6. Others

8. AMINOGLYCOSIDES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Shimadzu
• 10.2. Ringbio
• 10.3. Medscape
• 10.4. Fera Science
• 10.5. Sigma-Aldrich
• 10.6. Cipla Limited
• 10.7. Novartis AG
• 10.8. Vega Pharma Ltd
• 10.9. Insmed Corporation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations